- Home
- FBRX vs GDO Comparison
FBRX vs GDO Comparison
Compare FBRX & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- GDO
- Stock Information
- Founded
- FBRX N/A
- GDO 2009
- Country
- FBRX United States
- GDO United States
- Employees
- FBRX N/A
- GDO N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- GDO Finance Companies
- Sector
- FBRX Health Care
- GDO Finance
- Exchange
- FBRX Nasdaq
- GDO Nasdaq
- Market Cap
- FBRX 76.1M
- GDO 86.2M
- IPO Year
- FBRX N/A
- GDO N/A
- Fundamental
- Price
- FBRX $10.98
- GDO $11.37
- Analyst Decision
- FBRX Strong Buy
- GDO
- Analyst Count
- FBRX 4
- GDO 0
- Target Price
- FBRX $77.58
- GDO N/A
- AVG Volume (30 Days)
- FBRX 27.5K
- GDO 39.4K
- Earning Date
- FBRX 03-17-2025
- GDO 01-01-0001
- Dividend Yield
- FBRX N/A
- GDO 9.81%
- EPS Growth
- FBRX N/A
- GDO N/A
- EPS
- FBRX N/A
- GDO N/A
- Revenue
- FBRX N/A
- GDO N/A
- Revenue This Year
- FBRX N/A
- GDO N/A
- Revenue Next Year
- FBRX N/A
- GDO N/A
- P/E Ratio
- FBRX N/A
- GDO N/A
- Revenue Growth
- FBRX N/A
- GDO N/A
- 52 Week Low
- FBRX $4.11
- GDO $11.21
- 52 Week High
- FBRX $28.68
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- FBRX 36.53
- GDO 50.77
- Support Level
- FBRX $9.81
- GDO $11.40
- Resistance Level
- FBRX $13.13
- GDO $11.52
- Average True Range (ATR)
- FBRX 1.52
- GDO 0.09
- MACD
- FBRX -0.08
- GDO 0.01
- Stochastic Oscillator
- FBRX 18.17
- GDO 51.52
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.